Literature DB >> 29296901

Low fetal hemoglobin percentage is associated with silent brain lesions in adults with homozygous sickle cell disease.

David Calvet1, Titien Tuilier2, Nicolas Mélé1, Guillaume Turc1, Anoosha Habibi3, Nassim Ait Abdallah3, Loubna Majhadi4, François Hemery5, Myriam Edjlali6, Frédéric Galacteros3, Pablo Bartolucci3.   

Abstract

Silent white matter changes (WMCs) on brain imaging are common in individuals with sickle cell disease (SCD) and are associated with cognitive deficits in children. We investigated the factors predictive of WMCs in adults with homozygous SCD and no history of neurological conditions. Patients were recruited from a cohort of adults with homozygous SCD followed up at an adult sickle cell referral center for which steady-state measurements of biological parameters and magnetic resonance imaging scans of the brain were available. WMCs were rated by consensus, on a validated age-related WMC scale. The prevalence of WMCs was 49% (95% confidence interval [CI], 39%-60%) in the 83 patients without vasculopathy included. In univariable analysis, the patients who had WMCs were more likely to be older (P = .003) and to have hypertension (P = .02), a lower mean corpuscular volume (P = .005), a lower corpuscular hemoglobin concentration (P = .008), and a lower fetal hemoglobin percentage (%HbF) (P = .003). In multivariable analysis, only a lower %HbF remained associated with the presence of WMCs (odds ratio [OR] per 1% increase in %HbF, 0.84; 95% CI, 0.72-0.97; P = .021). %HbF was also associated with WMC burden (P for trend = .007). Multivariable ordinal logistic regression showed an inverse relationship between WMC burden (age-related WMC score divided into 4 strata) and HbF level (OR for 1% increase in %HbF, 0.89; 95% CI, 0.79-0.99; P = .039). Our study suggests that HbF may protect against silent WMCs, decreasing the likelihood of WMCs being present and their severity. It may therefore be beneficial to increase HbF levels in patients with WMCs.

Entities:  

Year:  2017        PMID: 29296901      PMCID: PMC5728628          DOI: 10.1182/bloodadvances.2017005504

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  48 in total

1.  Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease.

Authors:  J Schatz; R T Brown; J M Pascual; L Hsu; M R DeBaun
Journal:  Neurology       Date:  2001-04-24       Impact factor: 9.910

2.  Variation in fetal hemoglobin parameters and predicted hemoglobin S polymerization in sickle cell children in the first two years of life: Parisian Prospective Study on Sickle Cell Disease.

Authors:  M Maier-Redelsperger; C T Noguchi; M de Montalembert; G P Rodgers; A N Schechter; A Gourbil; D Blanchard; J P Jais; R Ducrocq; J Y Peltier
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

3.  Gelation of sickle cell hemoglobin in mixtures with normal adult and fetal hemoglobins.

Authors:  H R Sunshine; J Hofrichter; W A Eaton
Journal:  J Mol Biol       Date:  1979-10-09       Impact factor: 5.469

4.  Polymerase chain reaction amplification applied to the determination of beta-like globin gene cluster haplotypes.

Authors:  M Sutton; E E Bouhassira; R L Nagel
Journal:  Am J Hematol       Date:  1989-09       Impact factor: 10.047

5.  Silent cerebral infarction, income, and grade retention among students with sickle cell anemia.

Authors:  Allison A King; Mark J Rodeghier; Julie Ann Panepinto; John J Strouse; James F Casella; Charles T Quinn; Michael M Dowling; Sharada A Sarnaik; Alexis A Thompson; Gerald M Woods; Caterina P Minniti; Rupa C Redding-Lallinger; Melanie Kirby-Allen; Fenella J Kirkham; Robert McKinstry; Michael J Noetzel; Desiree A White; Janet K Kwiatkowski; Thomas H Howard; Karen A Kalinyak; Baba Inusa; Melissa M Rhodes; Mark E Heiny; Ben Fuh; Jason M Fixler; Mae O Gordon; Michael R DeBaun
Journal:  Am J Hematol       Date:  2014-08-04       Impact factor: 10.047

Review 6.  Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.

Authors:  Gregory J Kato; Mark T Gladwin; Martin H Steinberg
Journal:  Blood Rev       Date:  2006-11-07       Impact factor: 8.250

7.  The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).

Authors:  Ersi Voskaridou; Dimitrios Christoulas; Antonios Bilalis; Eleni Plata; Konstantinos Varvagiannis; George Stamatopoulos; Klio Sinopoulou; Aggeliki Balassopoulou; Dimitris Loukopoulos; Evangelos Terpos
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

8.  Central nervous system abnormalities in asymptomatic young patients with Sbeta-thalassemia.

Authors:  Dimitrios I Zafeiriou; Mara Prengler; Nikos Gombakis; Konsantinos Kouskouras; Marina Economou; Achileas Kardoulas; Chaido Tsantali; Athanasios Dimitriadis; Miranta Athanasiou; Fenella J Kirkham
Journal:  Ann Neurol       Date:  2004-06       Impact factor: 10.422

9.  Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia.

Authors:  A T Taher; K M Musallam; W Nasreddine; R Hourani; A Inati; A Beydoun
Journal:  J Thromb Haemost       Date:  2009-10-11       Impact factor: 5.824

10.  Asymptomatic cerebral lacunae in patients with chronic kidney disease.

Authors:  Shuzo Kobayashi; Toshio Ikeda; Hidekazu Moriya; Takayasu Ohtake; Hiromichi Kumagai
Journal:  Am J Kidney Dis       Date:  2004-07       Impact factor: 8.860

View more
  7 in total

Review 1.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 2.  Fetal hemoglobin in sickle cell anemia.

Authors:  Martin H Steinberg
Journal:  Blood       Date:  2020-11-19       Impact factor: 22.113

3.  Progression of central nervous system disease from pediatric to young adulthood in sickle cell anemia.

Authors:  Grace Champlin; Scott N Hwang; Andrew Heitzer; Juan Ding; Lisa Jacola; Jeremie H Estepp; Winfred Wang; Kenneth I Ataga; Curtis L Owens; Justin Newman; Allison A King; Robert Davis; Guolian Kang; Jane S Hankins
Journal:  Exp Biol Med (Maywood)       Date:  2021-08-18

4.  Fetal hemoglobin modulates neurocognitive performance in sickle cell anemia✰,✰✰.

Authors:  Andrew M Heitzer; Jennifer Longoria; Evadnie Rampersaud; Sara R Rashkin; Jeremie H Estepp; Victoria I Okhomina; Winfred C Wang; Darcy Raches; Brian Potter; Martin H Steinberg; Allison A King; Guolian Kang; Jane S Hankins
Journal:  Curr Res Transl Med       Date:  2022-03-15       Impact factor: 4.192

Review 5.  Genetic therapies for the first molecular disease.

Authors:  Phillip A Doerfler; Akshay Sharma; Jerlym S Porter; Yan Zheng; John F Tisdale; Mitchell J Weiss
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

6.  Hemodynamic provocation with acetazolamide shows impaired cerebrovascular reserve in adults with sickle cell disease.

Authors:  Lena Václavů; Benoit N Meynart; Henri J M M Mutsaerts; Esben Thade Petersen; Charles B L M Majoie; Ed T VanBavel; John C Wood; Aart J Nederveen; Bart J Biemond
Journal:  Haematologica       Date:  2018-12-06       Impact factor: 9.941

7.  Silent cerebral infarcts in patients with sickle cell disease: a systematic review and meta-analysis.

Authors:  Maite E Houwing; Rowena L Grohssteiner; Marjolein H G Dremmen; Ferdows Atiq; Wichor M Bramer; Anne P J de Pagter; C Michel Zwaan; Tonya J H White; Meike W Vernooij; Marjon H Cnossen
Journal:  BMC Med       Date:  2020-12-22       Impact factor: 8.775

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.